Abemaciclib CDK (cyclin-dependent kinase) inhibitor

Description Results NMA

progression free survival 0.54 [0.41; 0.72] median not reached vs. 14.7 mo Demonstrated

Abemaciclib (LY2835219) + nonsteroidal aromatase inhibitors (nSAI) (n=493)

vs.

Placebo + NSAI (n=0)

double-blind

Parallel groups

Sample size: 493/0

Primary endpoint: PFS

FU duration:

200 mg of abemaciclib orally twice daily (n=453)

vs.

150 mg of erlotinib (n=0)

open-label

Parallel groups

Sample size: 453/0

Primary endpoint: OS

FU duration:

phase 3